Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923312 | 0.95 | TSHR (0.57) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL28065 | 0.83 | TSHR (0.64) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706410 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706445 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706426 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706421 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706450 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706437 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706411 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706428 | 0.81 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403296-B1 | MONOMERS, POLYMERS, AND OPHTHALMIC LENSES AND CONTACT LENSES MADE BY USING THE SAME | JOHNSON & JOHNSON VISION CARE (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7112641-B2 | Monomer, polymers, and ophthalmic lenses and contact lenses made by using the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20040122249-A1 | Monomer, polymers, and ophthalmic lenses and contact lenses made by using the same | JOHNSON & JOHNSON VISION CARE, INC. | 2004-06-24 | — | — | US | disclosed |
| EP-1403296-A1 | MONOMERS, POLYMERS, AND OPHTHALMIC LENSES AND CONTACT LENSES MADE BY USING THE SAME | Johnson & Johnson Vision Care, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122249-A1 | Monomer, polymers, and ophthalmic lenses and contact lenses made by using the same | CRYAA, LOXL1, SMCHD1 | TSHR 4228/4885ALDH1A1 966/4885TDP1 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.